# Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell Lymphoma

> **NCT03054532** · PHASE2 · UNKNOWN · sponsor: **Singapore General Hospital** · enrollment: 22 (estimated)

## Conditions studied

- LYMPHOMA

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Lenali

## Key facts

- **NCT ID:** NCT03054532
- **Lead sponsor:** Singapore General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-07
- **Primary completion:** 2021-01
- **Final completion:** 2021-07
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2017-02-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03054532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03054532, "Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell Lymphoma". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT03054532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*